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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In this issue, Xie et al. present a case series of bone
echinococcosis treated with surgery or radiotherapy.1 Considering
that osseous echinococcosis is a rare manifestation of a neglected
disease with limited evidence for any form of treatment other than
radical surgery, the use of radiotherapy deserves a thorough
reﬂection. This is especially true as the idea of treating
echinococcosis with radiotherapy is not new and the data
compiled by generations of physicians and scientists over more
than 100 years are anything but promising.
2. Background
2.1. Cystic echinococcosis (CE)
Human cystic echinococcosis (CE), or hydatid disease, is a
cosmopolitan parasitic zoonosis caused by the larval stage of
Echinococcus granulosus, the ‘dog tape worm’. The parasite’s lifecycle
involves the dog as the deﬁnitive host, in which the adult parasite
resides in the proximal small bowel, and the sheep (as well as other
herbivores) as the intermediate host, in which the parasite’s
characteristic vesicular larval (metacestode) stage (the hydatid, or
hydatid cyst) forms in the viscera. In the accidental human inter-
mediate (dead-end) host, the characteristic cystic lesions are mainly
found in the liver (approximately 70%) and the lungs (approximately
20%), but virtually any part of the body may be affected, including the
bone. Osseous CE accounts for 0.5–4% of all CE cases, with the highly
vascularized large bones being most frequently affected: the
vertebral column in 50% of cases, followed by the pelvic bone
(14–21%), the femur (10–16%), the tibia (10%), and the ribs (8%).2–4
The signiﬁcant difference regarding the clinical course, manage-
ment, and outcome of osseous CE compared to visceral CE is the
fundamental difference in local evolution of the parasite in bone
compared to a visceral location. Visceral CE exhibits a concentrically
expansive growth pattern within the tissue conﬁned by the
formation of a (host tissue-derived) pericyst. Well-demarcated
and non-inﬁltrative, visceral CE exhibits the characteristics of a
benign tumour. However, in osseous CE pericyst formation does not
occur and the resulting microvesicular polycystic inﬁltration and
destruction of the bone resembles a malignant tumour (‘le cancer
blanc’5).6With the exception of cases where complete removal of the
affected bone is possible, the inﬁltrative nature of osseous CE does
not allow for unruptured resection of the microvesicular cysts, and
the spillage of their contents (cyst ﬂuid containing highly infective
protoscoleces) during surgery, leading to local recurrence of thehttp://dx.doi.org/10.1016/j.ijid.2015.01.005
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).disease, is nearly inevitable.7–10 Therefore the prognosis of patients
suffering from osseous CE is frequently compared to that of
malignant tumours, as described by Dew in 1928: ‘‘Prognosis in
vertebral hydatid disease is almost hopeless as regards complete
cure. This is due to the impossibility of removing by surgical means
all diseased bone, especially if the vertebral bodies are affected, to
the multiplicity of extra-osseous cysts, to the certainty of recurrent
pressure on the cord. . .’’.11
2.2. Alveolar echinococcosis (AE)
Alveolar echinococcosis (AE) caused by Echinococcus multi-
locularis, the ‘fox tape worm’, is conﬁned to the temperate and
arctic regions of the Northern Hemisphere. The parasite’s lifecycle
involves the fox (as well as other carnivores) as the deﬁnitive host
and wild rodents as intermediate hosts. In the accidental human
intermediate (dead-end) host, the lesions are almost exclusively
found in the liver (approximately 98%), while other anatomical
locations are only rarely affected. Bone infection is seen in 1% of
cases and, similar to osseous CE, spinal infection is reported in
approximately 50% of cases. In contrast to CE, AE typically exhibits
a progressive, inﬁltrative, malignant tumour-like growth pattern,
regardless of visceral or osseous involvement, which challenges
the treating physician with identical problems as in osseous CE.
3. Current treatment of osseous echinococcosis
Currently, the only curative treatment approach in osseous CE
and AE is radical surgery with complete resection of the affected
bone. However, in the majority of cases (involving the axial
skeleton – spine, pelvic bone, femur) this is usually impossible.12
For these patients, palliative surgery and prolonged (sometimes
indeﬁnite) medical treatment with benzimidazoles (albendazole,
mebendazole) currently constitutes the only therapeutic option.
Nevertheless, data on the efﬁcacy of benzimidazoles in osseous
echinococcosis are scarce, and considering that these drugs exhibit
a parasitostatic (in CE partial parasiticidal) effect on the parasite’s
larval stage, their contribution to cure or even to the prevention of
recurrence must not be overestimated.
4. Early in vitro and animal model irradiation experiments and
ﬁrst clinical case reports on radiotherapy attempts in human
echinococcosis
In 1927, De´ve´ et al. (in Rouen, France) published a review in
the journal Presse Me´dicale, summarizing the earliest studies oniety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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included De´ve´’s own work on the unsuccessful irradiation of
hydatid cysts transplanted into rabbits (1904), as well as his
consecutive experiments on in vitro irradiated E. granulosus
protoscoleces, which remained infectious even when inoculated
in rabbits after exposure to high-dose equivalents of 20 Sv (‘‘a dose
inevitably fatal for any mammal’’) (1922). In addition, the review
described case reports on the failure of radiotherapy by Bolboni
(Boston, 1922) and Lozano Manzen (Saragossa, 1923), as well as
observations suggesting some beneﬁt of radiotherapy by Josue´
Arce (Buenos Aires, 1923) and Carlos Henser (Buenos Aires, 1924).
The accruing controversy on the effect of radiotherapy between
De´ve´ and Arce drove De´ve´ to pursue his in vitro irradiation studies
of E. granulosus protoscoleces. Finally, De´ve´ demonstrated that
dystrophy and eventual death of the parasite was achievable, but
only by repetitive irradiation with extremely high doses of 200 Gy.
De´ve´ concluded that it would be impossible to apply such high
doses in vivo and hence noted that ‘‘treatment of hydatid cysts by
radiotherapy is an illusion’’. His conclusion was supported by other
studies conducted by Saraconi (1925) and Charbomel (1926).13
Similar to CE, controversial observations on the beneﬁt of
radiotherapy in AE have been reported, e.g., Ko¨nig (1921) claimed
beneﬁt in one case and Hehlfeder (1923) even reported cure of a
case. Perrin, who reviewed these case reports in his extensive
doctoral thesis on echinococcosis in 1932, noted the rather
anecdotal character of these reports, lacking proof of deﬁnitive
diagnosis as well as sufﬁcient follow-up: ‘‘as it stands for now, we
consider that radiotherapy is inefﬁcient in the treatment of
alveolar echinococcosis’’.13
5. Available clinical data on radiotherapy in osseous
echinococcosis
Despite the disappointing study results described above,
radiotherapy has repeatedly been tried as salvage therapy in
desperate cases of osseous echinococcosis after all surgical options
have been ruled out. The earliest detailed report on the use of
radiotherapy in osseous echinococcosis is a Spanish publication
reporting irradiation of advanced pelvic bone CE in 1949.14 After a
ﬁrst course of radiotherapy (cumulative dose 59 Gy in 32 fractions),
the patient suffered from recurrence of disease after 21 months,
and a second course (cumulative dose 54 Gy in 30 fractions) was
given, which achieved clinical stabilization of the patient.
However, the report was published after a follow-up time of only
3 months. In 1965, Fitzpatrick reported the use of radiotherapy in a
patient with extensive spinal CE and noted that no apparent
beneﬁt arose from this treatment.15 With the advent of a medical
treatment, marked by the introduction of mebendazole in the
1970s and albendazole in the early 1980s, no further case reports
on radiotherapy were published. Of note are two case reports on
radiotherapy attempts in cerebral AE (1998)16 and CE (2000).17 The
detailed medical history of the cerebral AE case (and the failure of
radiotherapy to destroy the parasite) has recently been reviewed.18
In 2010, Bao and colleagues published a case of osseous CE treated
with radiotherapy; however as this was published in Chinese, the
article was unfortunately not accessible for review.19
In recent years radiotherapy regained some interest as salvage
therapy in patients for whom surgery and medical treatment were
unable to halt chronic recurrence and progression of disease. In
2013, Ulger and colleagues reported the successful use of
radiotherapy (cumulative dose 25 Gy) with concomitant albenda-
zole therapy in a patient with sternal AE after the failure of multiple
surgical procedures and medical treatment.20 At the 1-year follow-
up, no clinical signs of local disease activity were observed. However,
the lesion was not biopsied, therefore preventing histological
conﬁrmation of treatment success. Recently, Liang et al. reported acase series of nine patients with pelvic bone CE of whom two were
treated with adjunct radiotherapy (cumulative dose 69 Gy in
23 fractions over 30 days) along with multiple surgical procedures
and medical treatment.21No recurrence was observed over a follow-
up of 4 and 6 years. However, as recurrence of disease may occur
with considerable delay, follow-up needs to be conducted over
many years, if not decades, to judge treatment efﬁcacy.22
In summary, the evidence to support the use of radiotherapy in
osseous echinococcosis is limited to case reports with ambiguous
results and largely insufﬁcient follow-up periods.
6. Available animal model data on irradiation of osseous CE
and AE
Experimental studies evaluating the use of radiotherapy in a
rodent bone CE model23 and in a rodent subcutaneous AE
model24,25 have been conducted and depict a dose-dependent
effect on protoscolex viability. For example, in the subcutaneous
AE model, irradiation doses of 20, 40, and 60 Gy resulted in
inhibition of larval growth by 50%, 72%, and 82%, respectively.24
(Considering the merely inhibitory effect observed in this study,
the publication’s title ‘‘Curative effect of radiotherapy at various
doses on subcutaneous alveolar echinococcosis in rats’’ is
inappropriate and misleading.)
7. Available in vitro data on irradiation of E. granulosus and E.
multilocularis metacestode tissue
Regarding the clinical application of irradiation, two targets
within the metacestode are relevant: the infective protoscoleces and
the stem cells of the germinal layer.26 In vitro studies on E. granulosus
protoscoleces showed that radiation with up to 300 Gy did not affect
their infectivity for hamsters or puppies.27 However, doses of 300–
600 Gy reduced the infectivity of protoscoleces and stunted the
consecutive development of the metacestode in mice. Moreover,
protoscoleces irradiated with doses of 400–600 Gy lost their
infectivity for puppies.28 Recent in vitro studies on E. multilocularis
metacestodes showed that irradiation with 50–150 Gy retarded
parasite growth but did not destroy the stem cells of the germinative
layer.26,28 Considering that: (1) the lethal effect of ionizing radiation
is strongly related to cell proliferation (i.e., it would mainly affect the
stem cells of the germinal layer), (2) the applicable irradiation dose is
limited by tolerance of the surrounding host tissue, (3) bone
metastases are irradiated with a cumulative dose of 20–40 Gy,29 and
osteosarcoma with doses of 50–70 Gy,30 it appears more than
unlikely that cure of echinococcosis can be achieved by radiothera-
py, even in the relatively radiation-tolerant bone tissue.
8. The presented study
The presented study constitutes the ﬁrst published case series
of bone echinococcosis in which radiotherapy was not used as an
adjunct treatment modality but as an alternative to surgery. Xie
et al. deserve gratitude for sharing their experiences with the often
highly complex clinical management of this particular form of the
disease. However, in light of the available preclinical data, the
general study approach remains controversial, if not disputable,
and the conclusions drawn by the authors need to be relativized.
Besides the study limitations already discussed by the authors,
some points need to be addressed and highlighted.
The description of the study as ‘retrospective’ remains inconclu-
sive, as study enrolment, treatment allocation, and follow-up was
clearly conducted in a prospective, observational manner.
To leave the decision on the treatment modality to the
individual patient in such a highly heterogeneous patient
population is not only problematic regarding the validity of the
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available in vitro and animal model data show that radiotherapy
cannot achieve clinical cure of osseous echinococcosis and that
radical surgery is currently the only proven potentially curative
treatment option, the allocation of patients with peripheral,
possibly completely resectable, bone lesions (e.g., clavicle, rib)
to radiotherapy denies them potential curative treatment.
Concerning the deﬁnitive diagnosis, many questions remain:
the title refers to ‘bone hydatid disease’, but the patients are
described as infected with Echinococcus sp, the serological results
are confusing (the results of the E. multilocularis-speciﬁc ‘Em2’
antigen assay described under Methods is labelled ‘Eg2’ in
Table 2 and the Results part; how the results of the ‘semi-
quantitative’ evaluation described under the Methods correspond
to the ﬁgures expressing ‘medians of positively signed numbers’ in
Table 2 is as unclear as the cut-offs for positivity), and the diagnosis
in the radiotherapy arm relied apparently solely on imaging and
serology, while it remains unclear whether histopathology was
done in all patients treated by surgery. In addition, all patients are
from a geographic region with high and overlapping endemicity of
E. granulosus and E. multilocularis, which hampers interpretation of
the serological results, and the speciﬁcity of imaging to differenti-
ate osseous echinococcosis from bone malignancies is limited.
Therefore, the patients have to be seen as histopathologically
‘conﬁrmed cases’ (all/most? surgical cases) and histopathologically
unconﬁrmed ‘probable cases’ (radiotherapy cases).
The authors fail to provide a rationale for the chosen irradiation
dose, which (in the light of existing data) appears to be arbitrary.
While the authors rightly discuss the inevitable spillage of cyst
ﬂuid during surgery of bone echinococcosis as a possible
explanation for the higher antibody titres observed in surgically
treated cases, it remains inconclusive why the authors decided to
infer treatment efﬁcacy from a single follow-up antibody titre after
a period of only 6 months. Multiple follow-up titres over a much
longer time period would have been necessary (and possible,
considering that the patients were followed for years) to allow a
critical conclusion. Considering these ﬂaws, the meaningfulness
and validity of the statistical analysis remains questionable.
Regarding the outcome measurement, the authors rightly
discuss the fact that radiotherapy is a well-established standard
treatment for pain relief in patients with osseous metastases, thus
questioning the usefulness of post interventional pain as an
outcome parameter. Unfortunately, the authors use the very same
parameter to deﬁne ‘relapse’ (by equating ‘painful’ with ‘relapse’),
which is puzzling.
The authors’ conclusions that radiotherapy may lead to ‘‘high
cure rates’’ and that ‘‘irradiation prevented dissemination of the
parasite to other tissues’’ remain speculative. This is especially true
given that the surrogate markers used to assess treatment outcome
(physical examination, serology, pain) are questionable, screening
for asymptomatic dissemination to other tissues by imaging is not
reported, and the follow-up periods still remain short for osseous
echinococcosis. In addition, it is worth pointing out that the
signiﬁcant shorter follow-up period in the radiotherapy arm
distorts, possibly even annihilates, the concluded beneﬁts of
radiotherapy.
The authors’ general statement that radiotherapy is ‘‘currently
receiving attention as an alternative to surgery’’ in bone
echinococcosis is ﬁrstly not supported by the very few case
reports published in recent years and secondly incorrect as
radiotherapy was used not as an ‘alternative’ but as salvage
therapy in these cases. Finally, the author’s statement that
‘‘radiotherapy . . . has the potential of being parasiticidal’’ appears
hasty, considering the substantial contradicting evidence from
available in vitro and animal studies, including the authors’ own
studies.23–259. Conclusions
9.1. Curative approach
Data compiled over almost 100 years by generations of
scientists and physicians trying to kill Echinococcus protoscoleces
and metacestodes by irradiation in vitro, in animal models, and in
patients, strongly indicate that curative radiotherapy of human
echinococcosis is not feasible (or ‘‘an illusion’’ as De´ve´ already
concluded almost 100 years ago). This conclusion is also supported
by previous animal studies conducted by or in cooperation with
the ﬁrst author of the presented study.23–25
Therefore, in light of existing data, radiotherapy cannot be
advocated as an alternative to surgery in osseous echinococcosis
where complete excision of the affected bone is possible, and thus
potentially curative. In fact, radiotherapy has to be regarded as
contraindicated in such cases.
9.2. Palliative approach
Even if the currently available data are scarce, it is not
impossible that radiotherapy may play a role as an adjunct
palliative treatment option in osseous echinococcosis. Whether
irradiation is capable of enhancing the effect of medical therapy (as
suggested by in vitro data on the concomitant use of irradiation
and albendazole treatment of E. multilocularis protoscoleces
provided by the same authors31), may be able to slow down
disease progression, or is limited to the contribution of pain relief,
still needs evaluation (Note: assessing the antiparasitic effect of
albendazole in vitro is doubtful considering the fact that
albendazole is a prodrug demanding hepatic metabolization to
the active compound albendazole sulfoxide, which does not occur
in vitro). However, the role of radiotherapy can only be deﬁned by
carefully planned and systematically conducted clinical trials with
sufﬁcient long-term follow-up of the patients. Until more evidence
is accumulated, the option of adjunct palliative radiotherapy
should be part of a multi-modal therapy concept and limited to
cases of advanced disease (mostly cases with extensive involve-
ment of the axial skeleton) where surgical options have reached
their limit and disease progression cannot be controlled by medical
treatment (or if medical treatment is not tolerated).
Conﬂict of interest: The author declares that he has no conﬂict of
interests.
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